Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis

BACKGROUND/AIM: We assessed suitable factors indicating newly developed lenvatinib (LEN) treatment for unresectable hepatocellular carcinoma (u‐HCC) by investigating real‐world clinical features of patients. MATERIALS/METHODS: One hundred fifty two u‐HCC patients, who receive LEN treatment from Marc...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Med
Main Authors: Hiraoka, Atsushi, Kumada, Takashi, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Kariyama, Kazuya, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Tada, Toshifumi, Toyoda, Hidenori, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Hayama, Korenobu, Imai, Michitaka, Joko, Kouji, Koizumi, Yohei, Hiasa, Yoichi, Michitaka, Kojiro, Kudo, Masatoshi
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley and Sons Inc. 2019
נושאים:
Clinical Cancer Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6639201/
https://ncbi.nlm.nih.gov/pubmed/31127698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2241
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים